JP2015509948A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509948A5 JP2015509948A5 JP2014558901A JP2014558901A JP2015509948A5 JP 2015509948 A5 JP2015509948 A5 JP 2015509948A5 JP 2014558901 A JP2014558901 A JP 2014558901A JP 2014558901 A JP2014558901 A JP 2014558901A JP 2015509948 A5 JP2015509948 A5 JP 2015509948A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 39
- 101000864751 Homo sapiens Seizure protein 6 homolog Proteins 0.000 claims description 30
- 102100030057 Seizure protein 6 homolog Human genes 0.000 claims description 30
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 12
- 239000000611 antibody drug conjugate Substances 0.000 claims description 12
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- 239000002254 cytotoxic agent Substances 0.000 claims description 5
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical group C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims 4
- 101100477420 Homo sapiens SEZ6 gene Proteins 0.000 claims 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 108010044540 auristatin Proteins 0.000 claims 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 2
- 229930195731 calicheamicin Natural products 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- -1 maytansinoid Chemical compound 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 description 5
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603203P | 2012-02-24 | 2012-02-24 | |
| US61/603,203 | 2012-02-24 | ||
| PCT/US2013/027476 WO2013126810A1 (en) | 2012-02-24 | 2013-02-22 | Anti sez6 antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018052506A Division JP2018127469A (ja) | 2012-02-24 | 2018-03-20 | 抗ｓｅｚ６抗体及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509948A JP2015509948A (ja) | 2015-04-02 |
| JP2015509948A5 true JP2015509948A5 (cg-RX-API-DMAC7.html) | 2016-04-14 |
| JP6401060B2 JP6401060B2 (ja) | 2018-10-03 |
Family
ID=47790548
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558901A Expired - Fee Related JP6401060B2 (ja) | 2012-02-24 | 2013-02-22 | 抗ｓｅｚ６抗体及び使用方法 |
| JP2018052506A Pending JP2018127469A (ja) | 2012-02-24 | 2018-03-20 | 抗ｓｅｚ６抗体及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018052506A Pending JP2018127469A (ja) | 2012-02-24 | 2018-03-20 | 抗ｓｅｚ６抗体及び使用方法 |
Country Status (20)
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201801444WA (en) * | 2012-02-24 | 2018-04-27 | Abbvie Stemcentrx Llc | Anti sez6 antibodies and methods of use |
| US11531028B2 (en) * | 2013-05-10 | 2022-12-20 | Nordic Bioscience A/S | Collagen type X alpha-1 assay |
| BR112016004242A8 (pt) * | 2013-08-28 | 2018-06-12 | Stemcentrx Inc | Métodos para conjugação sítio-específica de anticorpos e composições |
| US9993566B2 (en) * | 2013-08-28 | 2018-06-12 | Abbvie Stemcentrx Llc | SEZ6 modulators and methods of use |
| AU2014342610A1 (en) * | 2013-11-04 | 2016-06-02 | Abbvie Stemcentrx Llc | Anti-EFNA4 antibody-drug conjugates |
| SG11201604503XA (en) * | 2013-12-03 | 2016-07-28 | Agency Science Tech & Res | Cytotoxic antibody |
| PT3101132T (pt) * | 2014-01-29 | 2021-12-31 | Km Biologics Co Ltd | Anticorpo humano anti-transtirretina |
| EP3101131B1 (en) * | 2014-01-29 | 2020-08-19 | KM Biologics Co., Ltd. | Anti-transthyretin humanized antibody |
| AU2015218633A1 (en) | 2014-02-21 | 2016-09-01 | Abbvie Stemcentrx Llc | Anti-DLL3 antibodies and drug conjugates for use in melanoma |
| AU2015280436A1 (en) | 2014-06-23 | 2017-02-02 | Bionomics, Inc. | Antibodies that bind LGR4 |
| TW201617368A (zh) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
| WO2016057683A2 (en) | 2014-10-07 | 2016-04-14 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Novel anti-nodal antibodies and methods of using same |
| HK1257056A1 (zh) * | 2015-08-20 | 2019-10-11 | Abbvie Stemcentrx Llc | 抗dll3抗体药物缀合物以及使用方法 |
| WO2017060976A1 (ja) | 2015-10-06 | 2017-04-13 | パイオニア株式会社 | 光制御装置、光制御方法およびプログラム |
| WO2017087547A1 (en) * | 2015-11-17 | 2017-05-26 | Oncomed Pharmaceuticals, Inc. | Pd-l1-binding agents and uses thereof |
| AU2017228474C1 (en) | 2016-03-04 | 2024-03-28 | Abmuno Therapeutics Llc | Antibodies to TIGIT |
| US11214612B2 (en) | 2016-10-14 | 2022-01-04 | Nima Acquisition, Llc | Anti-gliadin antibodies, encoding nucleic acids and methods of detecting gliadin |
| CA3040421A1 (en) * | 2016-10-19 | 2018-04-26 | Novelogics Biotechnology, Inc. | Antibodies to mica and micb proteins |
| WO2018107116A1 (en) * | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby |
| CN110121507B (zh) * | 2016-12-23 | 2024-04-05 | 蓝鳍生物医药公司 | 抗sez6l2抗体和抗体药物缀合物 |
| EP3424527A1 (de) * | 2017-07-07 | 2019-01-09 | AVA Lifescience GmbH | Diagnostisches verfahren |
| CN111971303B (zh) | 2018-04-13 | 2022-05-17 | 苏州丁孚靶点生物技术有限公司 | 抗cd27抗体及其用途 |
| AU2019278870A1 (en) * | 2018-05-30 | 2020-10-29 | Abbvie Stemcentrx Llc | Anti-SEZ6 antibody drug conjugates and methods of use |
| US12091453B2 (en) * | 2018-07-11 | 2024-09-17 | Hedgehog, Inc. | Epitope specific to SMO protein, antibody recognizing same, and composition comprising same |
| CN112805036A (zh) | 2018-07-31 | 2021-05-14 | 第一三共株式会社 | 通过施用抗体-药物缀合物对转移性脑肿瘤的治疗 |
| EP3808774B1 (en) * | 2018-08-24 | 2025-04-16 | Jiangsu Hengrui Medicine Co., Ltd. | Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof |
| KR20230019152A (ko) | 2020-06-02 | 2023-02-07 | 아르커스 바이오사이언시즈 인코포레이티드 | Tigit에 대한 항체 |
| CN114106176B (zh) * | 2020-09-01 | 2024-04-09 | 深圳市菲鹏生物治疗股份有限公司 | Cd22抗体及其应用 |
| US20230287090A1 (en) * | 2020-09-02 | 2023-09-14 | The Feinstein Institutes For Medical Research | USE OF SARS-CoV-2 RECEPTOR BINDING MOTIF (RBM)-REACTIVE MONOCLONAL ANTIBODIES TO TREAT COVID-19 |
| IL303048A (en) | 2020-11-24 | 2023-07-01 | Novartis Ag | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| CN114790241B (zh) * | 2021-01-26 | 2024-12-13 | 北京免疫方舟医药科技有限公司 | 抗tigit抗体及其应用 |
| CN113307875B (zh) * | 2021-06-10 | 2022-09-02 | 福州迈新生物技术开发有限公司 | 抗TCRβF1蛋白单克隆抗体及其细胞株、制备方法和应用 |
| WO2023019174A2 (en) * | 2021-08-11 | 2023-02-16 | Apollos Diagnostics, Llc | Antibodies to sars-cov-2 |
| EP4525927A1 (en) | 2022-05-20 | 2025-03-26 | Novartis AG | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| EP4525928A1 (en) | 2022-05-20 | 2025-03-26 | Novartis AG | Antibody drug conjugates |
| CN115975036B (zh) * | 2022-08-18 | 2023-06-09 | 北京诺赛国际医学研究院 | 包含干细胞的药物组合物及其治疗癌症的用途 |
| AU2024270504A1 (en) * | 2023-05-08 | 2025-11-27 | Changzhou Hansoh Pharmaceutical Co., Ltd. | Antibody or antigen-binding fragment thereof, antibody-drug conjugate, and use thereof |
| CN117736331B (zh) * | 2024-02-04 | 2024-05-07 | 南昌大学第一附属医院 | 一种特异性结合psma胞外段的单克隆抗体及其应用 |
| WO2025167503A1 (en) * | 2024-02-05 | 2025-08-14 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-sez6/b7h3 antibodies and uses thereof |
| CN120365421B (zh) * | 2025-04-24 | 2025-11-04 | 成都古格尔生物技术有限公司 | 一种特异性抗sez6靶点的全人源抗体及其制备方法和应用 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| AU643109B2 (en) | 1990-12-14 | 1993-11-04 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| HUT76369A (en) | 1994-07-29 | 1997-08-28 | Smithkline Beecham Corp | Novel soluble protein compounds |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| EP1034298B1 (en) | 1997-12-05 | 2011-11-02 | The Scripps Research Institute | Humanization of murine antibody |
| WO2000012508A2 (en) | 1998-08-27 | 2000-03-09 | Spirogen Limited | Pyrrolbenzodiazepines |
| ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
| US20040067490A1 (en) * | 2001-09-07 | 2004-04-08 | Mei Zhong | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| EP1290026A2 (en) * | 2000-04-28 | 2003-03-12 | Eli Lilly And Company | Human sez6 nucleic acids and polypeptides |
| US7608704B2 (en) | 2000-11-08 | 2009-10-27 | Incyte Corporation | Secreted proteins |
| US6362331B1 (en) | 2001-03-30 | 2002-03-26 | Council Of Scientific And Industrial Research | Process for the preparation of antitumor agents |
| US20030211991A1 (en) * | 2001-04-17 | 2003-11-13 | Su Eric Wen | Human sez6 nucleic acids and polypeptides |
| CN1343774A (zh) | 2001-05-28 | 2002-04-10 | 复旦大学 | 一种癫痫相关蛋白编码序列,其编码的多肽、制法及用途 |
| JP2005533001A (ja) | 2002-03-04 | 2005-11-04 | メディミューン，インコーポレーテッド | インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法 |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| US7619068B2 (en) | 2003-05-09 | 2009-11-17 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
| GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
| KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
| PT1720881E (pt) | 2004-03-01 | 2013-02-04 | Spirogen Sarl | Derivados de 11-hidroxi-5h-pirrolo[2,1-c][1,4]benzodiazepin- 5-ona como intermediários chave para a preparação de pirrolobenzodiazepinas substituídas em c2 |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| US7189710B2 (en) | 2004-03-30 | 2007-03-13 | Council Of Scientific And Industrial Research | C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers |
| FR2869231B1 (fr) | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
| CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| US20070123448A1 (en) | 2005-11-23 | 2007-05-31 | The Hospital For Sick Children | Novel chemical entities affecting neuroblastoma tumor-initiating cells |
| ATE527262T1 (de) | 2006-01-25 | 2011-10-15 | Sanofi Sa | Neue tomaymycin derivate enhaltende zytotoxische mittel |
| CN101501187A (zh) | 2006-06-06 | 2009-08-05 | 田纳西大学研究基金会 | 富含赘生干细胞的组合物及包含其的方法 |
| NZ572561A (en) | 2006-06-07 | 2012-05-25 | Bioalliance Cv | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
| CA3153438C (en) | 2006-09-07 | 2024-03-12 | Scott & White Memorial Hospital | Methods and compositions based on diphtheria toxin-interleukin-3 conjugates |
| US8309354B2 (en) | 2007-01-22 | 2012-11-13 | Macrogenics West, Inc. | Human cancer stem cells |
| WO2008156712A1 (en) * | 2007-06-18 | 2008-12-24 | N. V. Organon | Antibodies to human programmed death receptor pd-1 |
| EP2676678A1 (en) | 2007-07-17 | 2013-12-25 | The General Hospital Corporation | Methods to identify and enrich populations of ovarian cancer stem cells and somatic stem cells and uses thereof |
| EP2022848A1 (en) | 2007-08-10 | 2009-02-11 | Hubrecht Institut | A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
| US20090155255A1 (en) | 2007-09-27 | 2009-06-18 | Biogen Idec Ma Inc. | Cd23 binding molecules and methods of use thereof |
| CN102083460A (zh) | 2008-01-18 | 2011-06-01 | 米迪缪尼有限公司 | 用于位点特异性偶联的半胱氨酸工程化抗体 |
| SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| WO2010037134A2 (en) | 2008-09-29 | 2010-04-01 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
| US8788213B2 (en) | 2009-01-12 | 2014-07-22 | Intrexon Corporation | Laser mediated sectioning and transfer of cell colonies |
| US20110020221A1 (en) | 2009-04-09 | 2011-01-27 | The Johns Hopkins University | Cancer stem cell expression patterns and compounds to target cancer stem cells |
| NZ598929A (en) | 2009-09-01 | 2014-05-30 | Abbvie Inc | Dual variable domain immunoglobulins and uses thereof |
| NZ602176A (en) * | 2010-03-12 | 2015-01-30 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| EP2558475A1 (en) | 2010-04-15 | 2013-02-20 | Spirogen Sàrl | Pyrrolobenzodiazepines used to treat proliferative diseases |
| RS52983B (sr) | 2010-04-15 | 2014-02-28 | Spirogen Sárl | Pirolobenzodiazepini i njihovi konjugati |
| CN103068405A (zh) | 2010-04-15 | 2013-04-24 | 西雅图基因公司 | 靶向吡咯并苯并二氮杂卓结合物 |
| GB201006340D0 (en) | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
| WO2012012801A2 (en) | 2010-07-23 | 2012-01-26 | The Johns Hopkins University | Device for capture, enumeration, and profiling of circulating tumor cells |
| WO2012019060A1 (en) * | 2010-08-05 | 2012-02-09 | Joslin Diabetes Center, Inc. | Predicting and treating diabetic complications |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| WO2013119964A2 (en) | 2012-02-08 | 2013-08-15 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| US20130061342A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| US20130061340A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| AU2011295722B2 (en) | 2010-09-03 | 2016-04-21 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| TWI882308B (zh) | 2010-09-29 | 2025-05-01 | 美商艾澤西公司 | 與191p4d12蛋白結合之抗體藥物共軛物(adc) |
| SG10201801444WA (en) * | 2012-02-24 | 2018-04-27 | Abbvie Stemcentrx Llc | Anti sez6 antibodies and methods of use |
| US9993566B2 (en) | 2013-08-28 | 2018-06-12 | Abbvie Stemcentrx Llc | SEZ6 modulators and methods of use |
| BR112016004242A8 (pt) * | 2013-08-28 | 2018-06-12 | Stemcentrx Inc | Métodos para conjugação sítio-específica de anticorpos e composições |
| WO2016064749A2 (en) | 2014-10-20 | 2016-04-28 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions, and methods of use |
| MA41645A (fr) * | 2015-03-04 | 2018-01-09 | Abbvie Stemcentrx Llc | Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation |
| CN110121507B (zh) | 2016-12-23 | 2024-04-05 | 蓝鳍生物医药公司 | 抗sez6l2抗体和抗体药物缀合物 |
-
2013
- 2013-02-22 SG SG10201801444WA patent/SG10201801444WA/en unknown
- 2013-02-22 MY MYPI2014002467A patent/MY178120A/en unknown
- 2013-02-22 EP EP19154773.6A patent/EP3539985A1/en not_active Withdrawn
- 2013-02-22 PE PE2014001301A patent/PE20150091A1/es active IP Right Grant
- 2013-02-22 CN CN201810153825.5A patent/CN108383909B/zh not_active Expired - Fee Related
- 2013-02-22 PH PH1/2020/500604A patent/PH12020500604A1/en unknown
- 2013-02-22 CA CA2865415A patent/CA2865415C/en active Active
- 2013-02-22 MX MX2014010094A patent/MX373141B/es active IP Right Grant
- 2013-02-22 AU AU2013203506A patent/AU2013203506B2/en not_active Ceased
- 2013-02-22 KR KR1020147026846A patent/KR102099073B1/ko not_active Expired - Fee Related
- 2013-02-22 US US14/380,665 patent/US9676850B2/en active Active
- 2013-02-22 EP EP13707529.7A patent/EP2817339B1/en active Active
- 2013-02-22 RU RU2014138420A patent/RU2691698C2/ru active
- 2013-02-22 WO PCT/US2013/027476 patent/WO2013126810A1/en not_active Ceased
- 2013-02-22 CN CN201380010534.6A patent/CN104334580B/zh not_active Expired - Fee Related
- 2013-02-22 JP JP2014558901A patent/JP6401060B2/ja not_active Expired - Fee Related
- 2013-02-22 SG SG11201405130UA patent/SG11201405130UA/en unknown
- 2013-02-22 NZ NZ631197A patent/NZ631197A/en not_active IP Right Cessation
- 2013-02-22 ES ES13707529T patent/ES2741936T3/es active Active
-
2014
- 2014-08-19 IL IL234208A patent/IL234208B/en active IP Right Grant
- 2014-08-21 MX MX2020003713A patent/MX2020003713A/es unknown
- 2014-08-22 CL CL2014002237A patent/CL2014002237A1/es unknown
- 2014-08-26 PH PH12014501914A patent/PH12014501914A1/en unknown
- 2014-09-23 CO CO14210871A patent/CO7151485A2/es unknown
- 2014-09-23 ZA ZA2014/06967A patent/ZA201406967B/en unknown
-
2016
- 2016-09-07 AU AU2016225828A patent/AU2016225828B2/en not_active Ceased
-
2017
- 2017-06-05 US US15/614,548 patent/US10533051B2/en not_active Expired - Fee Related
- 2017-11-08 CL CL2017002823A patent/CL2017002823A1/es unknown
-
2018
- 2018-03-20 JP JP2018052506A patent/JP2018127469A/ja active Pending
- 2018-08-31 AU AU2018223053A patent/AU2018223053B2/en not_active Expired - Fee Related
-
2019
- 2019-12-12 US US16/712,324 patent/US20200181256A1/en not_active Abandoned